Helius Med Technolog (HSDT) 1.9640 $HSDT
U.S. Army and Helius Medical Technologies Execute Sole Source Contract for the PoNS(TM) Device Testing and Development
Business Wire - Tue Jul 07, 9:15AM CDT
Helius Medical Technologies, Inc. (CSE:HSM) (OTCQB:HSDT) ("Helius" or the "Company"

announced that NeuroHabilitation Corporation ("NHC"

, a division of Helius, successfully executed a sole source cost sharing contract with the U.S. Army Medical Research and Materiel Command (USAMRMC). The contract will support Helius' registrational trial investigating the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS(TM)), a non-invasive brain stimulation device that is being developed for the treatment of balance disorder in patients with mild-to-moderate Traumatic Brain Injury (mTBI).
Helius Medical Technologies Announces Closing of CAD $875,558 Non-Brokered Private Placement
TheNewswire.ca - Fri Jun 26, 5:30PM CDT
(via Thenewswire.ca)
Helius Medical Technologies Announces Clinical Device Readiness for PoNS(TM) 4.0
Business Wire - Thu Jun 25, 11:21AM CDT
Helius Medical Technologies, Inc. (CSE: HSM) (OTCQB: HSDT) ("Helius"

is pleased to announce that it has successfully released the first clinical version of the Portable Neuromodulation Stimulator (PoNS(TM)) 4.0 device. The PoNS 4.0 device is manufactured by Ximedica LLC and will be used in Helius' registrational clinical trial, to investigate its safety and effectiveness for the treatment of balance disorder caused by traumatic brain injury.
Helius Medical Technologies Announces Clinical Device Readiness for PoNS (tm) 4.0
TheNewswire.ca - Thu Jun 25, 8:19AM CDT
(via Thenewswire.ca)
Helius Medical Technologies Amends and Re-files Historical Financial Statements and Material Change Report
ACCESSWIRE - Thu Jun 04, 7:12PM CDT
NEWTOWN, PA / ACCESSWIRE / June 4, 2015 / Helius Medical Technologies, Inc. (CSE: HSM) (OTCQB: HSDT) ("HMT", or the "Company"

- As a result of a review by the British Columbia Securities Commission, we are issuing the following press release to clarify our disclosure.
Helius Medical Technologies Achieves Full Enrollment in Canadian MS Feasibility Study
Business Wire - Wed May 20, 9:15AM CDT
Helius Medical Technologies ("Helius", "HMT", or the "Company"

announced that it has achieved full enrollment for its Multiple Sclerosis pilot clinical trial at the Montreal Neurological Institute. The trial, "Examining the efficacy of non-invasive neuromodulation in reducing symptoms of Multiple Sclerosis," launched in February 2015, is a 14-subject, blinded feasibility study investigating Helius' Portable Neuromodulation Stimulator (PoNS(TM)) and physiotherapy protocol on the rehabilitation of balance and gait symptoms in subjects with Multiple Sclerosis.
Helius Medical Technologies Announces Closing of Cad $2,208,110 Non-Brokered Private Placement
ACCESSWIRE - Thu Apr 30, 5:07PM CDT
NEWTOWN, PA / ACCESSWIRE / April 30, 2015 / Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ("Helius", or the "Company"

is pleased to announce that it has closed a non-brokered private placement (the "Financing"

raising gross proceeds of CAD $2,208,110 (approximately USD $1,825,937) by the issuance of 849,273 units (each a "Unit"

at a price of CAD $2.60 per Unit (USD $2.15 per Unit). Each Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a "Warrant"

. Each whole Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of approximately CAD $3.62 per share (USD $3.00 per share) for a period of thirty-six (36) months from the closing date of the Financing.
Helius Medical Technologies Inventors' Granted US Patent No. 14/341,141
Business Wire - Tue Apr 14, 9:20AM CDT
Helius Medical Technologies, Inc. (CSE:HSM)(OTCQB:HSDT) ("Helius", or the "Company"

announced today that the US Patent and Trademark Office (USPTO) issued a third patent related to its Portable Neuromodulation Stimulation (PoNS(TM)) device and the associated therapeutic modality. U.S. Patent No. 14/341,141 "Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function", issued on April 10, 2015, is directed to a non-invasive neuromodulation therapy that uses intraoral cutaneous stimulation in conjunction with cognitive exercise.
Helius Medical Technologies to Start Its Registrational Clinical Trial
Business Wire - Mon Apr 13, 12:04PM CDT
Helius Medical Technologies, Inc. (CSE:HSM) (OTCQB:HSDT) ("Helius"

is pleased to announce that it recently met with the US Food and Drug Administration ("FDA" or the "Agency"

as part of the Agency's pre-submission (pre-sub) process regarding Helius's protocol for its double-blind, randomized, sham-controlled study of the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS(TM)) 4.0 device for cranial nerve noninvasive neuromodulation (CN-NINM) training in subjects with a chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI).
Helius Medical Technologies Grants Stock Options
ACCESSWIRE - Mon Mar 16, 4:49PM CDT
NEWTOWN, PA / ACCESSWIRE / March 16, 2015 / Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ( "Helius" or "the Company"

, a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, announces that it has granted incentive stock options, exercisable to purchase up to an aggregate of 100,000 shares of the Company, to a director of Helius.
Helius Medical Technologies Announces First Three Subjects Enrolled in Canadian Multiple Sclerosis Feasibility Study
Business Wire - Thu Feb 19, 9:15AM CST
Helius Medical Technologies ("Helius", or the "Company"

announced the enrollment of the first three subjects in the Multiple Sclerosis ("MS"

feasibility study at the Montreal Neurological Institute and Hospital and Concordia's PERFORM Center. The trial, "Examining the efficacy of Non-invasive Neuromodulation in reducing symptoms of Multiple Sclerosis", is a double-blind, sham-controlled study of the safety and efficacy of Helius' Portable Neuromodulation Stimulator (PoNS(TM)) device, an investigational medical device that is designed to induce neuromodulation by stimulating the cranial nerves found in the tongue. A total of 14 subjects will receive treatment with the non-invasive brain stimulation device and concomitant physiotherapy designed to improve both balance and gait. The primary endpoint, at 14-weeks, is improvement in gait as quantified by the Dynamic Gait Index (DGI), Sensory Organization Test (SOT) and Functional Magnetic Resonance imaging (fMRI). The study is expected to conclude this summer.